A new global direction presents itself
By now followers of the Reluctant Advocate will no doubt have grasped the expansion of work that naturally occurs when running…
By now followers of the Reluctant Advocate will no doubt have grasped the expansion of work that naturally occurs when running…
One mother’s personal story about her young son’s diagnosis with atypical HUS. Connected to the broader themes of what happens after a rare disease diagnosis as working parents strive to navigate, childcare, emotional stress, and family impacts.
aHUS Patients contributed two questions to the aHUS Patients Research Agenda: 1. Is there an optimal way in which a complement…
The reluctant advocate story continues: aHUSUK had received the Evaluation Consideration Document the week before Rare Disease Day 2014 and we…
News announced in recent days that, unlike in the USA , Europe does not intend to extend the patent for Eculizumab…
The aHUS alliance affiliates put the question: Is there a significant difference in outcome between having a complement inhibitor before or…
The aHUS Alliance continues its series ‘The Reluctant Advocate’, chronicling the UK’s journey to gain access to eculizumab for treating those…
A large part of patient advocacy is about raising awareness of the illness they suffer. This is particularly true of rare…
These days a kidney transplant may not feature much in the thoughts of new onset aHUS patients, most of them can…